drugset / Trial / NCT07545564

A Study on Mucosal Specific IgA Immunokinetics After Administration of Nasal Spray Live Attenuated Influenza Vaccine

NCT07545564 ↗

Phase 4 Enrolling by invitation 200 enrolled Changchun BCHT Biotechnology Co.
RandomizedParallel-groupDouble-blindPrevention

Summary

Mucosal-specific sIgA antibody GMT;Evaluate the achievement of 2-fold and 4-fold increases in the geometric mean titer (GMT) of specific nasal mucosal sIgA antibodies after vaccination

Timeline

Start
2026-04-09
Primary completion
2026-04-23
Completion
2026-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject LAIV Vaccine — Intranasal

Indications